My Treatment Approach: Modern Perspectives on the Management of Chronic Phase CML (CP-CML)

EP. 1: The Impact of Patient Comorbidities on Frontline Treatment Selection and Assessing the Different Frontline Treatment Options for Chronic Phase CML (CP-CML)

June 30th 2025

Drs. Elias Jabbour and Michael Mauro discuss how patient comorbidities influence the selection of frontline tyrosine kinase inhibitor (TKI) therapy in chronic phase CML, highlighting specific comorbidity-TKI combinations to avoid and strategies for optimizing individualized treatment.

EP. 2: The Importance of Achieving Early Clinical Milestones During Treatment of CP-CML

July 11th 2025

Panelists discuss the importance of achieving deep molecular response in chronic myeloid leukemia (CML) as both a clinical milestone and a patient-centered goal, highlighting its role in reducing relapse risk, enabling treatment-free remission, and aligning medical outcomes with patients’ desire for a functional cure and improved quality of life.

EP. 3: Weighing Treatment Efficacy and Toxicity in the Frontline Setting for CP-CML

July 11th 2025

Panelists discuss the complexities of selecting frontline therapy for chronic myeloid leukemia (CML), emphasizing the need to balance efficacy, adverse effect profiles, dose management strategies, and financial considerations to ensure long-term disease control, patient adherence, and quality of life.

EP. 4: Clinical Scenario: Disease and Patient-Related Factors Affecting Treatment Selection in the Frontline Setting

July 18th 2025

Panelists discuss the individualized selection of tyrosine kinase inhibitors (TKIs) in a high-risk chronic myeloid leukemia case, highlighting how comorbidities, risk scores, and long-term goals such as treatment-free remission influence frontline therapy decisions to balance efficacy, safety, and quality of life.

EP. 5: Assessing and Preparing Patients for TKI-Specific Treatment-Related Adverse Events

July 18th 2025

Panelists discuss the importance of evaluating and communicating the adverse effect profiles of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia, emphasizing how day-to-day tolerability, comorbidities, and patient preferences inform personalized treatment selection to support adherence and quality of life.

EP. 6: Identifying Patients at Risk for TKI-Related Treatment Intolerance

July 25th 2025

Panelists discuss the importance of understanding adverse event profiles and patient-specific risk factors in selecting chronic myeloid leukemia (CML) therapies, emphasizing personalized treatment approaches that balance efficacy with tolerability to optimize long-term adherence and quality of life.

EP. 7: Strategies to Assist Patients Experiencing TKI-Related Treatment Intolerance

July 25th 2025

Panelists discuss the critical role of open communication and patient partnership in managing adverse events during treatment, highlighting proactive education, dose adjustments, and collaborative care strategies to enhance adherence, quality of life, and long-term outcomes in chronic disease management.

EP. 8: The Clinical Impact of Treatment Intolerance and Nonadherence in CP-CML

August 1st 2025

Panelists discuss the critical impact of treatment adherence and intolerance on outcomes in chronic myeloid leukemia (CML), emphasizing compassionate communication, patient education, and proactive management of adverse effects to support sustained therapy, improve quality of life, and achieve long-term remission goals.

EP. 9: Introducing Treatment-Free Remission (TFR) to Patients Early in Their Treatment Course for CP-CML

August 1st 2025

Panelists highlight that early communication about treatment-free remission (TFR), personalized therapy selection, and proactive management of adverse effects are key to motivating adherence and achieving long-term remission in chronic myeloid leukemia (CML).

EP. 10: Determining Patient Eligibility for TFR

August 8th 2025

Panelists emphasize that eligibility for treatment discontinuation in chronic myeloid leukemia (CML) is individualized, balancing clinical factors with patient preferences and readiness through shared decision-making and ongoing support.